Strs Ohio Raises Position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX)

Strs Ohio grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRXGet Rating) by 31.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 254,700 shares of the company’s stock after buying an additional 60,300 shares during the quarter. Strs Ohio owned 0.08% of Amneal Pharmaceuticals worth $514,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of AMRX. Swiss National Bank lifted its holdings in Amneal Pharmaceuticals by 8.6% during the first quarter. Swiss National Bank now owns 229,600 shares of the company’s stock worth $957,000 after buying an additional 18,100 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Amneal Pharmaceuticals by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 566,337 shares of the company’s stock valued at $2,361,000 after purchasing an additional 6,097 shares during the last quarter. MetLife Investment Management LLC raised its stake in Amneal Pharmaceuticals by 169.4% in the 1st quarter. MetLife Investment Management LLC now owns 58,313 shares of the company’s stock worth $243,000 after acquiring an additional 36,668 shares during the last quarter. Panagora Asset Management Inc. raised its stake in Amneal Pharmaceuticals by 109.5% in the 1st quarter. Panagora Asset Management Inc. now owns 165,694 shares of the company’s stock worth $691,000 after acquiring an additional 86,613 shares during the last quarter. Finally, BlackRock Inc. raised its stake in Amneal Pharmaceuticals by 1.3% in the 1st quarter. BlackRock Inc. now owns 7,082,702 shares of the company’s stock worth $29,535,000 after acquiring an additional 91,072 shares during the last quarter. Institutional investors own 32.79% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 1st.

Insider Activity at Amneal Pharmaceuticals

In other news, major shareholder Tpg Gp A, Llc sold 3,884,600 shares of the company’s stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $2.34, for a total value of $9,089,964.00. Following the completion of the sale, the insider now directly owns 12,328,767 shares of the company’s stock, valued at $28,849,314.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 26.78% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Stock Down 1.8 %

AMRX stock opened at $2.17 on Thursday. Amneal Pharmaceuticals, Inc. has a one year low of $1.95 and a one year high of $4.98. The company has a debt-to-equity ratio of 13.62, a quick ratio of 1.07 and a current ratio of 1.74. The firm’s 50 day moving average price is $2.27 and its 200-day moving average price is $2.21. The firm has a market cap of $658.80 million, a PE ratio of -2.49, a PEG ratio of 0.13 and a beta of 1.35.

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) last posted its quarterly earnings results on Friday, November 4th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The business had revenue of $545.56 million during the quarter, compared to analyst estimates of $564.58 million. Amneal Pharmaceuticals had a positive return on equity of 57.89% and a negative net margin of 6.17%. On average, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.58 EPS for the current year.

About Amneal Pharmaceuticals

(Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NYSE:AMRXGet Rating).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.